Molecular diagnostic challenges for non‐retinal developmental eye disorders in the United Kingdom. Issue 3 (23rd August 2020)

• Record Type: Journal Article
• Authors: Jackson, Daniel; Malka, Samantha; Harding, Philippa; Palma, Juliana; Dunbar, Hannah; Moosajee, Mariya
• Other Names: Hufnagel Robert guestEditor.; Walter Michael guestEditor.; Arno Gavin guestEditor.
• Is Part Of: American journal of medical genetics. Volume 184:Issue 3(2020)
• Page Start: 578
• Page End: 589
• Publication Date: 2020-08-23
• Subjects: developmental eye disorders -- genetic eye disease -- next generation sequencing -- targeted gene panels -- whole genome sequencing; Medical genetics -- Periodicals; 616.04205
• DOI: 10.1002/ajmg.c.31837
• Languages: English
• ISSNs: 1552-4868

Abstract

Abstract: Overall, approximately one‐quarter of patients with genetic eye diseases will receive a molecular diagnosis. Patients with developmental eye disorders face a number of diagnostic challenges including phenotypic heterogeneity with significant asymmetry, coexisting ocular and systemic disease, limited understanding of human eye development and the associated genetic repertoire, and lack of access to next generation sequencing as regarded not to impact on patient outcomes/management with cost implications. Herein, we report our real world experience from a pediatric ocular genetics service over a 12 month period with 72 consecutive patients from 62 families, and that from a cohort of 322 patients undergoing whole genome sequencing (WGS) through the Genomics England 100, 000 Genomes Project; encompassing microphthalmia, anophthalmia, ocular coloboma (MAC), anterior segment dysgenesis anomalies (ASDA), primary congenital glaucoma, congenital cataract, infantile nystagmus, and albinism. Overall molecular diagnostic rates reached 24.9% for those recruited to the 100, 000 Genomes Project (73/293 families were solved), but up to 33.9% in the clinic setting (20/59 families). WGS was able to improve genetic diagnosis for MAC patients (15.7%), but not for ASDA (15.0%) and congenital cataracts (44.7%). Increased sample sizes and accurate human phenotype ontology (HPO) terms are required to improve diagnostic accuracy. The significant mixed complex ocular phenotypes distort these rates and lead to missed variants if the correct gene panel is not applied. Increased molecular diagnoses will help to explain the genotype–phenotype relationships of these developmental eye disorders. In turn, this will lead to improved integrated care pathways, understanding of disease, and future therapeutic development.